派林生物(000403) - 2017 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2017 was CNY 132,909,500.94, a decrease of 19.05% compared to CNY 164,181,419.42 in the same period last year[8]. - Net profit attributable to shareholders was CNY 19,510,890.14, an increase of 10.40% from CNY 17,672,978.61 year-on-year[8]. - Basic earnings per share increased by 16.67% to CNY 0.07 from CNY 0.06 in the same period last year[8]. Cash Flow and Operating Activities - Net cash flow from operating activities was negative CNY 26,323,210.91, a decline of 174.77% compared to CNY 35,207,745.62 in the previous year[8]. - Cash received from sales of goods and services decreased by 43.47% year-on-year, primarily due to reduced cash sales from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Net cash flow from operating activities decreased by 174.77% year-on-year, mainly due to reduced cash sales from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Cash and cash equivalents net increase decreased by 300.65% year-on-year, primarily due to reduced cash sales revenue.[16]. Assets and Shareholder Equity - Total assets at the end of the reporting period were CNY 1,262,436,850.63, up 1.54% from CNY 1,243,318,051.17 at the end of the previous year[8]. - Net assets attributable to shareholders increased by 3.52% to CNY 573,863,326.60 from CNY 554,352,436.46 at the end of the previous year[8]. - The company had a weighted average return on equity of 3.50%, up from 3.23% in the previous year[8]. Shareholding Structure - The total number of ordinary shareholders at the end of the reporting period was 17,036[11]. - The largest shareholder, Zhixing Group Co., Ltd., held 22.61% of the shares, amounting to 61,621,064 shares, with 50,000,000 shares pledged[11]. - There were no significant changes in the shareholding structure or any repurchase transactions during the reporting period[12]. Operating Costs and Expenses - Operating costs decreased by 49.77% year-on-year, primarily due to a reduction in sales volume from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Sales expenses increased by 335.68% year-on-year, mainly due to changes in sales policies at Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Employee compensation payable decreased by 54.42% at the beginning of the year, mainly due to the issuance of accrued employee compensation.[16]. - Other expenses decreased by 97.99% year-on-year, mainly due to fewer fixed asset disposals by Guangdong Shuanglin Biopharmaceutical Co., Ltd. in the previous period.[16]. Other Income and Impairments - Other income increased by 100% year-on-year, mainly due to the transfer of special funds and tax refunds from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Asset impairment losses increased by 81.60% year-on-year, mainly due to a decrease in the reversal of prior impairment provisions at Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Accounts receivable increased by 2282.03% compared to the beginning of the year, mainly due to increased sales receivables from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16].